Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Non Operating Income (2013 - 2026)

Scynexis' (SCYX) quarterly Non Operating Income came in at $15.2 million in Q2 2026, up 466.97% on a YoY basis from $2.7 million in Q2 2025, and up 447.98% quarter-over-quarter from -$4.4 million in Q1 2026.

Analysis

Scynexis (SCYX) Non Operating Income (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Non Operating Income for 14 consecutive years, with $15.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non Operating Income rose 466.97% year-over-year to $15.2 million; the trailing twelve-month figure through Jun 2026 stood at $12.4 million (down 25.77% YoY), and the FY2025 full-year result was $7.5 million, down 53.29% from the prior year.
  • Non Operating Income rose to $15.2 million in Q2 2026 per SCYX's latest filing, from -$4.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $15.2 million in Q2 2026 and bottomed at -$23.2 million in Q1 2023.
  • Historically, Non Operating Income has averaged $2.6 million across 5 years, with a median of $3.6 million in 2023.
  • The sharpest annual moves came in 2022 and 2023: Non Operating Income surged 583.7% in 2022, then tumbled 341.93% in 2023.
  • Over 5 years, Non Operating Income stood at $8.1 million in 2022, then plunged by 55.08% to $3.6 million in 2023, then grew by 0.72% to $3.6 million in 2024, then slumped by 52.32% to $1.7 million in 2025, then jumped by 773.46% to $15.2 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods registered $15.2 million, -$4.4 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -73.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 387.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 234.30 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn -53.64 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Scynexis 58.41 Mn -56.29 Mn - 15.17 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.17 Mn
Mar 31, 2026 -4.36 Mn
Dec 31, 2025 1.74 Mn
Sep 30, 2025 -186,000.00
Jun 30, 2025 2.68 Mn
Mar 31, 2025 3.22 Mn
Dec 31, 2024 3.64 Mn
Sep 30, 2024 7.12 Mn
Jun 30, 2024 -5.22 Mn
Mar 31, 2024 10.45 Mn
Dec 31, 2023 3.62 Mn
Sep 30, 2023 8.34 Mn
Jun 30, 2023 5.75 Mn
Mar 31, 2023 -23.19 Mn
Dec 31, 2022 8.05 Mn
Sep 30, 2022 -7.78 Mn
Jun 30, 2022 8.39 Mn
Mar 31, 2022 9.59 Mn
Dec 31, 2021 -6.95 Mn
Sep 30, 2021 18.79 Mn